. 2011 May;7(3 Suppl):e38s–e45s. doi: 10.1200/JOP.2011.000303

Table 1.

Model Inputs

Model	Base Case Value	Source
Distribution of patients according to risk group
Low risk	52.7%	Humana
Intermediate risk	34.6%	Humana
High risk	12.7%	Humana
Relative reduction in risk with chemotherapy
Patients at low risk	131.0%	Paik et al¹⁰
Patients at intermediate risk	61.0%	Paik et al¹⁰
Patients at high risk	26.0%	Paik et al¹⁰
Resource costs
Chemotherapy	$7,026	Humana
Supportive care	$9,606	Humana
Adverse events	$1,761	Humana
Recurrence	$104,000	Oratz et al¹¹
Utility of health states
QALY loss associated with chemotherapy	0.5	Muss et al,¹² Simes et al¹³
QALY loss associated with recurrence	9.1	Muss et al,¹² Piccart et al,¹⁴ Ravdin et al,¹⁵ Simes et al¹³
QALY loss associated with second primary cancer caused by chemotherapy	9.0	Muss et al,¹² Piccart et al,¹⁴ Ravdin et al,¹⁵ Simes et al¹³
Chemotherapy recommendation before RS
Before RS low risk	50%	Meta-analysis
Before RS intermediate risk	55%	Meta-analysis
Before RS high risk	60%	Meta-analysis
Other parameters
Mean age, years	59	Humana
Discount rate	3%	Weinstein et al¹⁶
Time horizon	40	Lifetime horizon

NOTE. See Appendix Table A2 for distributions used for sensitivity analyses.

Abbreviations: QALY, quality-adjusted life-year; RS, recurrence score.